Clinical Trial Update: Zanubrutinib and Venetoclax in CLL (ZANU-VEN) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (ZANU-VEN) evaluating the combination of zanubrutinib and venetoclax for chronic lymphocytic leukemia and small lymphocytic lymphoma is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: RECRUITING